46 related articles for article (PubMed ID: 10415871)
21. Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.
Iyer R; Evans AE; Qi X; Ho R; Minturn JE; Zhao H; Balamuth N; Maris JM; Brodeur GM
Clin Cancer Res; 2010 Mar; 16(5):1478-85. PubMed ID: 20179224
[TBL] [Abstract][Full Text] [Related]
22. On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology.
Thiele CJ; Li Z; McKee AE
Clin Cancer Res; 2009 Oct; 15(19):5962-7. PubMed ID: 19755385
[TBL] [Abstract][Full Text] [Related]
23. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
Miknyoczki SJ; Chang H; Klein-Szanto A; Dionne CA; Ruggeri BA
Clin Cancer Res; 1999 Aug; 5(8):2205-12. PubMed ID: 10473107
[TBL] [Abstract][Full Text] [Related]
24. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
25. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
26. Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior.
Miknyoczki SJ; Lang D; Huang L; Klein-Szanto AJ; Dionne CA; Ruggeri BA
Int J Cancer; 1999 May; 81(3):417-27. PubMed ID: 10209957
[TBL] [Abstract][Full Text] [Related]
27. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
Dionne CA; Camoratto AM; Jani JP; Emerson E; Neff N; Vaught JL; Murakata C; Djakiew D; Lamb J; Bova S; George D; Isaacs JT
Clin Cancer Res; 1998 Aug; 4(8):1887-98. PubMed ID: 9717816
[TBL] [Abstract][Full Text] [Related]
28. The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.
Miknyoczki SJ; Dionne CA; Klein-Szanto AJ; Ruggeri BA
Ann N Y Acad Sci; 1999 Jun; 880():252-62. PubMed ID: 10415871
[TBL] [Abstract][Full Text] [Related]
29. Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models.
Ruggeri BA; Miknyoczki SJ; Singh J; Hudkins RL
Curr Med Chem; 1999 Sep; 6(9):845-57. PubMed ID: 10495355
[TBL] [Abstract][Full Text] [Related]
30. RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy.
Yao HP; Hudson R; Wang MH
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188360. PubMed ID: 32234337
[TBL] [Abstract][Full Text] [Related]
31. Neurotrophin-Trk receptor interactions in neoplasia: a possible role in interstitial and perineural invasion in ductal pancreatic cancer.
Miknyoczki SJ; Klein-Szanto AJ; Ruggeri BA
Crit Rev Oncog; 1996; 7(1-2):89-100. PubMed ID: 9109499
[TBL] [Abstract][Full Text] [Related]
32. Trk receptor tyrosine kinases in metastasis and cancer therapy.
Regua AT; Doheny D; Arrigo A; Lo HW
Discov Med; 2019 Oct; 28(154):195-203. PubMed ID: 31928627
[TBL] [Abstract][Full Text] [Related]
33. Roles of the nervous system in pancreatic cancer.
Wakiya T; Ishido K; Yoshizawa T; Kanda T; Hakamada K
Ann Gastroenterol Surg; 2021 Sep; 5(5):623-633. PubMed ID: 34585047
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
